Trial Profile
Randomized, Double-Blind, Placebo-Controlled, Safety and Tolerability Study of Escalating Single Doses of ITI-214 in Patients With Systolic Heart Failure
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 27 Sep 2021
Price :
$35
*
At a glance
- Drugs Lenrispodun (Primary)
- Indications Heart failure
- Focus Therapeutic Use
- Sponsors Intra-Cellular Therapies
- 20 Sep 2021 Results presented in an Intra-Cellular Therapies media release.
- 23 Dec 2020 Status changed from active, no longer recruiting to completed.
- 29 Jun 2020 Status changed from recruiting to active, no longer recruiting, according to a Intra-Cellular Therapies media release.